Pfizer Inc

Dow Jones

Dow Jones Industrial Average Rallies Today Ahead of FOMC Decision

The Dow Jones Industrial Average is rallying early Wednesday ahead of today's critical announcement by the Federal Reserve on interest rates.

Despite outrage from President Donald Trump, the U.S. central bank is expected to hike interest rates for the fourth time in 2018, raising concerns that the Fed will put a halt on America's economic expansion and rattle investor confidence for the balance of the year.

Here's everything you need to know about the market today...

Dow Jones

Dow Jones Today Poised to Climb for Fifth Straight Day of 2018

The Dow Jones today is off to one of its best starts to a New Year in more than a decade.

Dow futures are down 12 points this morning despite high optimism for technology stocks. Today, one of the most important events in the tech sector, the Consumer Electronics Show, kicks off and will likely fuel significant optimism for the sector all week.

Here's a look at today's most important market events and stocks, plus a look at today's economic calendar...


Cash In on the Legal Weed Derivative That's Changing the War on Pain

Bill is a big fan of this biotech, which focuses on the big problem of chronic pain. It's a company that's looking at this malady in new ways.

He's also showing you how to find more stocks like this one – companies that are establishing whole new paradigms in biotechnology, life sciences, and pharmaceuticals.

And there's an entirely new area of focus in pain treatment right now - legal weed...


This Company Proves the "Ten-Bagger Stock" Is No Myth

Back in August 2011, for the very first edition of Private Briefing, I recommended a Belgian biotech firm that I said was "like buying an independent drug development lab" for less than nine bucks a share – $8.60, in fact.

I zeroed in on the company's collaborative partnerships on a whole slew of drug development programs.

Now, I love to see this in a biotech stock, because it means that some of the usual risks of owning a small, clinical-stage company – running out of money, or the risk of one trial failure wiping out the firm – were minimized.

That arrangement was critical in the massive, almost tenfold gains that followed. (And, as you'll see, it's going to be just as important in the bigger gains I see down the road for the folks who bought this company.)

I've recommended these shares for my subscribers more than a dozen times since, each time before a fresh bumper crop of profits. This company has given more than 931% in peak gains for Private Briefing subscribers, and a market-crushing 26% since I first shared it with Money Morning Members in September 2016.

There's a very specific reason I see these gains getting even bigger for everyone in the future...